AstraZeneca AB (manufacturing, quality control, primary and secondary packaging, batch release)

The drug is intended for the treatment of adult patients with chronic lymphocytic leukemia (CLL). It may be used either as monotherapy or in combination with obinutuzumab (if the disease has not been previously treated), or as monotherapy (if the patient has already undergone previous courses of treatment).

Dosage form: capsules, hard

ATC: L01EL02